Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bayer Aktienges ADR (BAYRY)

Bayer Aktienges ADR (BAYRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,307,268
  • Shares Outstanding, K 3,929,700
  • Annual Sales, $ 51,558 M
  • Annual Income, $ -3,183 M
  • EBIT $ 841 M
  • EBITDA $ 11,686 M
  • 60-Month Beta 1.10
  • Price/Sales 0.50
  • Price/Cash Flow 1.76
  • Price/Book 0.65
  • Price/Earnings ttm 4.17
  • Earnings Per Share ttm 1.62
  • Most Recent Earnings $0.25 on 08/06/24
  • Next Earnings Date 11/13/24 [--]
  • Annual Dividend & Yield 0.02 (0.34%)
  • Most Recent Dividend 0.022 on 04/29/24
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.17
  • Number of Estimates 1
  • High Estimate 0.17
  • Low Estimate 0.17
  • Prior Year 0.10
  • Growth Rate Est. (year over year) +70.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.3850 +3.21%
on 11/06/24
8.0800 -18.44%
on 10/08/24
-1.5900 (-19.44%)
since 10/07/24
3-Month
6.3850 +3.21%
on 11/06/24
8.5800 -23.19%
on 09/30/24
-0.4900 (-6.92%)
since 08/07/24
52-Week
6.3850 +3.21%
on 11/06/24
11.3300 -41.84%
on 11/17/23
-4.6300 (-41.27%)
since 11/07/23

Most Recent Stories

More News
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea...

BAYRY : 6.5900 (+2.33%)
NVS : 107.08 (+0.25%)
REGN : 824.48 (+0.96%)
SNY : 51.73 (+0.92%)
Novartis Gets CHMP Recommendation for Kisqali in Broader Population

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali (ribociclib)...

BAYRY : 6.5900 (+2.33%)
LLY : 797.45 (+2.71%)
NVS : 107.08 (+0.25%)
Bayer Seeks Approval for Elinzanetant for Vasomotor Symptoms in EU

Bayer BAYRY announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (“EMA”) for its pipeline candidate elinzanetant.The MAA is seeking approval...

BAYRY : 6.5900 (+2.33%)
LLY : 797.45 (+2.71%)
NVS : 107.08 (+0.25%)
Roche Wins FDA Nod for Breast Cancer Drug in First-Line Setting

Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer, under the brand name Itovebi.The drug is approved in combination with Pfizer’s Ibrance...

BAYRY : 6.5900 (+2.33%)
NVS : 107.08 (+0.25%)
RHHBY : 38.1700 (+1.06%)
SNY : 51.73 (+0.92%)
Regeneron Gains 13.5% Year to date: How to Play the Stock?

Shares of Regeneron Pharmaceuticals, Inc. REGN have gained 13.5% in the year so far against the industry’s decline of 2.8%.The stock has outperformed the sector during this timeframe but underperformed...

BAYRY : 6.5900 (+2.33%)
REGN : 824.48 (+0.96%)
RHHBY : 38.1700 (+1.06%)
SNY : 51.73 (+0.92%)
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer

For Immediate ReleaseChicago, IL – October 8, 2024 – Today, Zacks Equity Research Eli Lilly LLY, AstraZeneca AZN, Pfizer PFE, Sanofi SNY and Bayer BAYRY.Industry: Big PharmaLink: https://www.zacks.com/commentary/2346520/5-large-drug-stocks-to-watch-from-a-thriving-industryThe...

BAYRY : 6.5900 (+2.33%)
AZN : 64.69 (+1.32%)
LLY : 797.45 (+2.71%)
PFE : 27.46 (+0.37%)
SNY : 51.73 (+0.92%)
5 Large Drug Stocks to Watch From a Thriving Industry

The drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of promising new medicines and pipeline successes. Obesity drugs of Novo Nordisk and...

BAYRY : 6.5900 (+2.33%)
AZN : 64.69 (+1.32%)
LLY : 797.45 (+2.71%)
PFE : 27.46 (+0.37%)
SNY : 51.73 (+0.92%)
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs

AbbVie ABBV announced in a regulatory filing that it is lowering its previously issued guidance for 2024 adjusted earnings per share by 4 cents per share to account for acquired in-process research and...

BAYRY : 6.5900 (+2.33%)
AZN : 64.69 (+1.32%)
LLY : 797.45 (+2.71%)
ABBV : 200.51 (-0.34%)
Bayer Reports Positive Safety Data on Parkinson's Disease Drug

Bayer Ag BAYRY and its wholly owned subsidiary BlueRock Therapeutics LP announced positive 24-month data from an early-stage study on experimental candidate bemdaneprocel (BRT-DA01).Bemdaneprocel, an investigational...

BAYRY : 6.5900 (+2.33%)
LLY : 797.45 (+2.71%)
PFE : 27.46 (+0.37%)
Bayer Submits Application for Label Expansion of Prostate Cancer Drug

Bayer BAYRY announced the submission of a supplemental new drug application (sNDA) to the FDA for darolutamide.The sNDA is seeking approval of darolutamide, in combination with androgen deprivation therapy...

BAYRY : 6.5900 (+2.33%)
LLY : 797.45 (+2.71%)
REGN : 824.48 (+0.96%)
PFE : 27.46 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses....

See More

Key Turning Points

3rd Resistance Point 6.6300
2nd Resistance Point 6.5700
1st Resistance Point 6.5050
Last Price 6.5900
1st Support Level 6.3800
2nd Support Level 6.3200
3rd Support Level 6.2550

See More

52-Week High 11.3300
Fibonacci 61.8% 9.4410
Fibonacci 50% 8.8575
Fibonacci 38.2% 8.2740
Last Price 6.5900
52-Week Low 6.3850

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar